Vividion Therapeutics completes acquisition of Tavros Therapeutics to expand functional genomics capabilities
Acquiring Company
Vividion Therapeutics, Inc.
Acquired Company
Tavros
PrincetonDurhamBiotechnologyBiotechnologyDescription
Vividion Therapeutics, Inc. has announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. With this acquisition, Vividion aims to expand its functional genomics expertise and capabilities, bringing proprietary methods for genomic screening to identify new target opportunities and support discovery efforts towards known targets.
Quick answer
Vividion Therapeutics, Inc. is acquiring Tavros, announced January 8, 2025. Vividion Therapeutics, Inc. is based in Princeton, New Jersey, United States.
- How much did Vividion Therapeutics, Inc. pay for Tavros?
- The deal value was not disclosed.
- What does Vividion Therapeutics, Inc. do?
- Vividion Therapeutics
- Where are Vividion Therapeutics, Inc. and Tavros based?
- Vividion Therapeutics, Inc. is based in Princeton, New Jersey, United States. Tavros is based in Durham, North Carolina, United States.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- UroGen Pharma Ltd. acquires next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. (February 20, 2025)
- Flourish Research acquires Diablo Clinical Research to expand therapeutic coverage (February 18, 2025)
- MMS acquires Exploristics and KerusCloud to expand biostatistics and data science capabilities (February 13, 2025)
- Biolog, Inc. acquires Anaerobe Systems, Inc. to expand its expertise in microbiology research (February 12, 2025)
- Novartis to acquire Anthos Therapeutics for up to $3.1 Billion, $3.1B (February 11, 2025)
- Pan-Am Dental completes strategic acquisitions of JB Dental Lab and Avaneer Dental Studio, solidifying its position as a top 10 dental lab group (February 10, 2025)
Who to call at Vividion Therapeutics, Inc., and when
When Vividion Therapeutics, Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Vividion Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vividion Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vividion Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vividion Therapeutics, Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Tavros?
Tavros was acquired by Vividion Therapeutics, Inc., based in Princeton. The deal was reported on January 8, 2025. Vividion Therapeutics Vividion Therapeutics, Inc. is privately held and operates in Biotechnology.
When did Vividion Therapeutics, Inc. acquire Tavros?
Vividion Therapeutics, Inc.'s acquisition of Tavros was reported on January 8, 2025. Vividion Therapeutics, Inc. has announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Tavros do?
Tavros is the company acquired in this transaction. It is privately held, operating in Biotechnology, and is based in Durham.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.